Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines when serum and CSF biomarker tests (including AQP4-IgG and MOG-IgG assays and oligoclonal band analysis) are covered or not covered for diagnosis of MS, NMOSD, and MOG-EM for BlueCross BlueShield of Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Biomarker Testing
CSF Oligoclonal Band Testing
CSF oligoclonal band analysis MEETS COVERAGE CRITERIA for diagnosis of MS when ANY of the following are present:
Paired CSF/serum sampling required to demonstrate CSF-specific OCBs; OCBs may substitute for dissemination-in-time per 2017 McDonald criteria.
CSF examination is strongly recommended in some circumstances when clinical/MRI evidence is insufficient (Thompson et al., 2018).
Lower pre-test probability populations warrant CSF testing to aid diagnosis.
OCB demonstration can allow a diagnosis of MS when dissemination-in-space criteria are met but dissemination-in-time is lacking.
Serum AQP4-IgG and MOG-IgG Assays
Serum indirect fluorescence assay or FACS (cell-based) assays for AQP4-IgG and MOG-IgG MEET COVERAGE CRITERIA when ALL of the following are met:
Clinical presentations compatible with NMOSD/MOG-EM per guidance.
Imaging/electrophysiology supportive of CNS demyelination required.
At least one listed high-risk feature must be present to meet coverage criteria.
Cell-based assays (microscopy or FACS) are recommended as gold standard due to superior sensitivity/specificity; serum is the preferred specimen for MOG-IgG.
Not Medically Necessary / Not Covered Tests
Tests that DO NOT MEET COVERAGE CRITERIA:
Requests outside the specified clinical indications will be denied due to lack of published evidence of clinical benefit.
Peptide-based ELISA and Western blot are not recommended for MOG; immunohistochemistry is not recommended due to lower sensitivity/specificity.
CSF AQP4-IgG or MOG-IgG testing is not covered per policy.
Clinical indications summarized
Clinical indications and supporting evidence summarized from guideline and studies:
International Panel on Diagnosis of Multiple Sclerosis (2018) supports CSF OCBs for diagnosis; Simonsen et al. found IgG index >0.7 PPV >99%.
Thompson et al., IPND, and NMOSD panel recommendations emphasize cell-based assays and serum specimen preference for MOG-IgG.
Cantó et al., Benkert et al., and Martin et al. provide evidence for sNfL and CSF NfL as markers of disease activity and prognosis.
ELISA, Western blot, immunohistochemistry, and other non–cell-based serum assays for NMOSD or MOG‑EM are explicitly listed as tests that do not meet coverage criteria. Requests for these assay types should be treated as non‑covered per the policy statement and may be denied when submitted for evaluation of AQP4‑IgG or MOG‑IgG.
The policy references IPND guidance noting that for MOG‑IgG the recommended methods are indirect fluorescence/CBA or FACS targeting full‑length human MOG. It also states that general (non‑selective) MOG‑IgG testing is discouraged in patients with a progressive disease course because of a very low pre‑test probability; therefore routine, non‑targeted MOG screening in progressive presentations is not supported.
There are no explicit procedural exclusions listed in the cited sections beyond the assay‑type exclusions; the document excerpts focus on evidence, guidance citations, and reimbursement context rather than listing additional procedural or specimen‑handling exclusions.
The policy states that serum biomarker tests for multiple sclerosis performed in clinical situations other than those specifically described in the coverage criteria are considered not medically necessary. In practice, this means serum biomarker testing for MS without meeting the listed clinical indications or assay requirements is not supported by the policy.
Consistent with IPND recommendations cited in the policy, routine, non‑selective MOG‑IgG testing in patients with a progressive disease course is not recommended due to very low pre‑test probability and lower expected diagnostic yield.
Systematic reviews and policy assessments cited in the document emphasize diagnostic test performance and specificity. The policy therefore implies that assays or testing strategies without demonstrated diagnostic accuracy and clinical utility (for example, non‑recommended ELISA/Western blot methods) are not recommended and may be excluded from coverage.
Applicable Procedure and Reference Codes
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified |
| 83916 | Oligoclonal immune (oligoclonal bands) |
| 84182 | Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each |
| 86051 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; enzyme-linked immunosorbent immunoassay (ELISA) |
| 86052 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; cell-based immunofluorescence assay (CBA), each |
| 86053 | Aquaporin-4 (neuromyelitis optica [NMO]) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each |
| 86362 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA), each |
| 86363 | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; flow cytometry (ie, fluorescence-activated cell sorting [FACS]), each |
| 88341 | Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure) |
| 88342 | Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure |
| K161951 (510k referenced) | FDA 510(k) decision document cited |
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required for testing when the requested service must be demonstrated to meet the specific clinical coverage criteria described in this policy (for example, CSF oligoclonal band analysis and specialty antibody assays such as AQP4-IgG and MOG-IgG). Requests should include sufficient clinical information to allow review against the coverage criteria.
- Prior authorization required when medical necessity is not clearly documented
- Include paired CSF and serum sample information for OCB testing when applicable
Coding and Documentation Requirement
Providers must submit appropriate coding and complete clinical documentation to support the use of the CPT/HCPCS codes listed in the policy (see Applicable CPT/HCPCS Procedure Codes). Documentation should link the submitted code(s) to the indication, relevant clinical findings, imaging or electrophysiology results, and any prior testing or treatments.
Prior Authorization May Be Required for Specialty Biomarker Assays
Prior authorization may be required for specialty biomarker assays (for example, AQP4-IgG, MOG-IgG, and ultra-sensitive NfL assays). When submitting requests, include assay methodology and laboratory performing the test because assay performance and methodology (cell-based assay, FACS, ELISA, immunohistochemistry, etc.) affect clinical interpretation and coverage determination.
- Cell-based assays (CBA) and FACS for MOG/AQP4 are preferred methods; ELISA/Western blot/immunohistochemistry are not recommended for MOG and may not meet coverage
- Specify whether testing is serum or CSF and timing relative to acute attack or immunosuppression
Government Policy Precedence
Government policies (Local Coverage Determinations, National Coverage Determinations, and applicable state Medicaid rules) take precedence over this policy. If there is a conflict for a particular member, the applicable government policy will be used for the coverage determination.
- Consult current LCD/NCD and state Medicaid guidance when evaluating coverage for Medicare or Medicaid members
Potential Reimbursement Risk
Assays with poor or uncertain diagnostic performance may present a reimbursement risk. Requests for tests using non-recommended methodologies or for indications not supported by published literature may be denied or subject to payment denial.
- Denial risk for serum biomarker tests for MS outside listed indications
- Denial risk for ELISA, Western blot, immunohistochemistry, or other non-recommended serum/CSF assays for NMOSD or MOG-EM
Required Clinical Documentation
Required clinical documentation must demonstrate that the indication meets covered criteria. For OCB testing, document atypical clinical, laboratory, or imaging features, insufficient MRI/clinical evidence, or membership in a population where MS is less common (eg, pediatric, older adults). For NMOSD/MOG testing, document compatible clinical syndrome and supporting radiologic/electrophysiologic findings or other listed risk features.
- For OCBs: paired CSF and serum results, description of atypical features, and how results will impact management
- For AQP4/MOG: clinical syndrome (optic neuritis, myelitis, brainstem encephalitis), MRI/electrophysiology findings, and any high-risk features (eg, bilateral optic neuritis, longitudinally extensive spinal cord lesion, severe visual loss)
Clinical Justification and Timing for Testing
Clinical justification and timing for testing should be clearly stated. Indicate whether MRI or clinical evidence is insufficient, whether presentation is atypical, and the timing of specimen collection relative to symptom onset or immunosuppressive therapy (eg, MOG-IgG is highest during acute attack and when not receiving immunosuppression).
- If testing is to support initiation of long-term disease-modifying therapy, state this explicitly
- Note prior treatments and their dates (eg, monoclonal antibodies, platform therapies) when interpreting sNfL or antibody levels
Supporting Diagnostic Evidence
Supporting diagnostic evidence should be provided when available. Cite comparative performance (eg, IgG index vs OCBs) and relevant guideline statements that support the requested test, and include imaging, electrophysiology, histopathology, or CSF findings that corroborate the clinical impression.
- Provide MRI findings (DIS/DIT status), CSF cell counts, protein, and other biomarkers as applicable
- Reference guideline-based rationale when the test substitutes for dissemination in time (eg, CSF OCBs per McDonald criteria guidance)
Therapy Response Context for sNfL
Therapy-response context for serum neurofilament light chain (sNfL): include prior and current therapies in documentation because sNfL levels change with treatment. High-potency monoclonal therapies may reduce sNfL Z scores to control levels, whereas platform therapies (interferons, glatiramer acetate) may not; this can inform risk stratification and therapy decisions.
- Report recent therapies and timing relative to specimen collection
- Include age and BMI adjustments or reference percentile/Z-score methodology if available
Background and Context
Multiple sclerosis is an immune‑mediated inflammatory demyelinating disorder with a variable clinical course. Magnetic resonance imaging (MRI) is the primary diagnostic tool to demonstrate dissemination in space and time; cerebrospinal fluid oligoclonal IgG bands (OCBs) can supplement MRI and clinical findings and, in some situations, substitute for dissemination in time under diagnostic criteria. The policy cites guideline and systematic review literature to place biomarker testing in the context of diagnostic pathways, differential diagnosis (including NMOSD and MOG‑EM), and prognostic assessment.
Key Definitions and Biomarker Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.